Skip to main content
SpringerLink
Log in

Antineoplastics

Lack of efficacy: 28 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ogusu S, et al. EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy. Investigational New Drugs 40 : 1342-1349, No. 6, Dec 2022. Available from: URL: https://www.springer.com/journal/10637

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antineoplastics. Reactions Weekly 1967, 48 (2023). https://doi.org/10.1007/s40278-023-43855-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-43855-5

Search

Navigation